» Articles » PMID: 39536432

PCCA Variant Rs16957301 is a Novel AKI Risk Genotype-specific for Patients Who Receive ICI Treatment: Real-world Evidence from All of Us Cohort

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2024 Nov 13
PMID 39536432
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Immune checkpoint inhibitors (ICIs) enhance the immune system's ability to target and destroy cancer cells, but can also trigger immune-related adverse events (irAEs), such as acute kidney injury (ICI-AKI), complicating patient management. Limited knowledge of genetic predispositions to ICI-AKI highlights the need for genomic studies to improve therapeutic strategies.

Objective: To identify genetic predispositions for ICI-AKI using large-scale real-world data.

Methods: A systematic literature search led to 14 candidate variants related to irAEs. We performed a candidate variant association study with these variants using the All of Us cohort. An ICI-treated cohort and a general cohort were established to evaluate ICI-AKI risk. Logistic regression, adjusted for sex, evaluated the impact of each candidate genotype, separately for self-reported and ancestry-estimated race. Kaplan-Meier survival analysis assessed genetic effects on AKI-free survival.

Results: The ICI cohort (n = 414) showed a one-year AKI incidence rate of 23.2 %, significantly higher than the general cohort (6.5 %, n = 213,282). The rs16957301 variant (chr13:100324308, T > C) in the PCCA gene was a significant risk genotype for ICI-AKI among self-reported White (Beta=0.93, CI: 0.32 - 1.54, ORs= 2.53, Bonferroni-corrected P-value=0.047) and ancestry estimated Europeans (Beta = 0.94, CI: 0.31 - 1.57, ORs= 2.56, Bonferroni-corrected P-value=0.044). Self-reported White with the rs16957301 risk genotypes (TC/CC) developed AKI significantly earlier (3.6 months) compared to the reference genotype (TT, 7.0 months, log-rank P = 0.04). Consistent results were found in ancestry-estimated Europeans. This variant did not present significant AKI risks in the general cohort (Beta: -0.008-0.035, FDR: 0.75-0.99).

Conclusion: Our findings suggest that rs16957301 in PCCA may serve as an ICI-AKI risk marker in Caucasians. Further studies are needed to validate this association and explore risks in other populations.

Citing Articles

Deep Learning-Based Automatic Segmentation Combined with Radiomics to Predict Post-TACE Liver Failure in HCC Patients.

Li S, Liu K, Rong C, Zheng X, Cao B, Guo W J Hepatocell Carcinoma. 2024; 11:2471-2480.

PMID: 39712947 PMC: 11663388. DOI: 10.2147/JHC.S499436.

References
1.
Stein C, Burtey S, Mancini J, Pelletier M, Sallee M, Brunet P . Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrol Dial Transplant. 2020; 36(9):1664-1674. DOI: 10.1093/ndt/gfaa137. View

2.
Johnson D, Nebhan C, Moslehi J, Balko J . Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022; 19(4):254-267. PMC: 8790946. DOI: 10.1038/s41571-022-00600-w. View

3.
Garcia-Carro C, Bolufer M, Bury R, Castaneda Z, Munoz E, Felip E . Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrol Dial Transplant. 2021; 37(5):887-894. DOI: 10.1093/ndt/gfab034. View

4.
Luo J, Martucci V, Quandt Z, Groha S, Murray M, Lovly C . Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Cancer Res. 2021; 27(18):5131-5140. PMC: 8815444. DOI: 10.1158/1078-0432.CCR-21-0921. View

5.
Zhao Q, Chen Y, Huang W, Zhou H, Zhang W . Drug-microbiota interactions: an emerging priority for precision medicine. Signal Transduct Target Ther. 2023; 8(1):386. PMC: 10560686. DOI: 10.1038/s41392-023-01619-w. View